Impax Asset Management Group plc increased its position in shares of Marsh & McLennan Companies, Inc. (NYSE:MMC – Free Report) by 5.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,812,150 shares of the financial services provider’s stock after purchasing an additional 95,540 shares during the period. Marsh & McLennan Companies makes up approximately 1.6% of Impax Asset Management Group plc’s portfolio, making the stock its 18th largest position. Impax Asset Management Group plc owned about 0.37% of Marsh & McLennan Companies worth $403,200,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Marsh & McLennan Companies in the second quarter valued at approximately $3,710,000. Czech National Bank increased its holdings in shares of Marsh & McLennan Companies by 6.7% in the 3rd quarter. Czech National Bank now owns 100,175 shares of the financial services provider’s stock valued at $22,348,000 after purchasing an additional 6,282 shares in the last quarter. Raymond James & Associates lifted its stake in shares of Marsh & McLennan Companies by 2.6% in the second quarter. Raymond James & Associates now owns 925,411 shares of the financial services provider’s stock valued at $195,003,000 after purchasing an additional 23,133 shares during the period. O Shaughnessy Asset Management LLC grew its position in Marsh & McLennan Companies by 8.8% during the first quarter. O Shaughnessy Asset Management LLC now owns 68,383 shares of the financial services provider’s stock worth $14,086,000 after buying an additional 5,554 shares during the period. Finally, Cetera Investment Advisers increased its holdings in Marsh & McLennan Companies by 236.7% in the first quarter. Cetera Investment Advisers now owns 55,496 shares of the financial services provider’s stock valued at $11,431,000 after buying an additional 39,013 shares in the last quarter. Institutional investors and hedge funds own 87.99% of the company’s stock.
Insider Buying and Selling
In other Marsh & McLennan Companies news, Director Oscar Fanjul sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $221.55, for a total transaction of $553,875.00. Following the completion of the sale, the director now directly owns 48,549 shares in the company, valued at $10,756,030.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.30% of the company’s stock.
Marsh & McLennan Companies Trading Up 0.4 %
Marsh & McLennan Companies (NYSE:MMC – Get Free Report) last issued its earnings results on Thursday, October 17th. The financial services provider reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.02. Marsh & McLennan Companies had a return on equity of 32.65% and a net margin of 16.82%. The business had revenue of $5.70 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same period last year, the company posted $1.57 EPS. The business’s quarterly revenue was up 5.9% on a year-over-year basis. As a group, research analysts forecast that Marsh & McLennan Companies, Inc. will post 8.7 earnings per share for the current year.
Marsh & McLennan Companies Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Friday, October 4th will be issued a dividend of $0.815 per share. This represents a $3.26 dividend on an annualized basis and a dividend yield of 1.48%. The ex-dividend date of this dividend is Friday, October 4th. Marsh & McLennan Companies’s payout ratio is currently 40.15%.
Analyst Ratings Changes
MMC has been the subject of several research reports. UBS Group lifted their price objective on Marsh & McLennan Companies from $255.00 to $259.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Keefe, Bruyette & Woods lifted their price objective on Marsh & McLennan Companies from $209.00 to $212.00 and gave the stock an “underperform” rating in a research report on Tuesday, October 22nd. The Goldman Sachs Group set a $220.00 price target on Marsh & McLennan Companies and gave the stock a “sell” rating in a research report on Friday, October 18th. BMO Capital Markets upped their price objective on Marsh & McLennan Companies from $217.00 to $228.00 and gave the company a “market perform” rating in a research report on Tuesday, October 22nd. Finally, Roth Mkm lifted their price objective on Marsh & McLennan Companies from $220.00 to $230.00 and gave the stock a “neutral” rating in a research report on Friday, October 18th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Marsh & McLennan Companies currently has an average rating of “Hold” and a consensus target price of $225.33.
Check Out Our Latest Report on Marsh & McLennan Companies
Marsh & McLennan Companies Company Profile
Marsh & McLennan Companies, Inc, a professional services company, provides advice and solutions to clients in the areas of risk, strategy, and people worldwide. It operates through Risk and Insurance Services, and Consulting segments. The Risk and Insurance Services segment offers risk management services, such as risk advice, risk transfer, and risk control and mitigation solutions, as well as insurance and reinsurance broking, strategic advisory services, and analytics solutions, and insurance program management services.
Further Reading
- Five stocks we like better than Marsh & McLennan Companies
- Stock Dividend Cuts Happen Are You Ready?
- Intel: Is Now the Time to Be Brave?Â
- Most active stocks: Dollar volume vs share volume
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Stock Market Upgrades: What Are They?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Want to see what other hedge funds are holding MMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marsh & McLennan Companies, Inc. (NYSE:MMC – Free Report).
Receive News & Ratings for Marsh & McLennan Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marsh & McLennan Companies and related companies with MarketBeat.com's FREE daily email newsletter.